“…(2010) confirmed that MBP contains an α‐amylase inhibitor with a molecular weight of 27 kDa and a specific activity of 14.5 U/(mg of protein), lower than that of common bean (495.2–1925.5 U/(mg of protein)). In addition, MBP peptides obtained from Alcalase hydrolysis showed higher α‐glucosidase inhibitory activity (42.17%) (Li et al., 2022) than that obtained from lupin (22.61%) (Fadimu et al., 2022), yellow field pea ( Pisum sativum L.) (38.39%) (Awosika & Aluko, 2019), and common bean (15.04%) (Ohara et al., 2021) but showed lower than pinto Durango bean (76.4%) (Oseguera‐Toledo et al., 2015), Lima Bean ( Phaseolus lunatus L.) (69.4%) (Castaneda‐Perez et al., 2021), chickpea ( Cicer arietinum L.) (56%) (Quintero‐Soto et al., 2021), and black bean ( Phaseolus vulgaris L.) (66.1%) (Mojica & de Mejia, 2016). Meanwhile, the results showed that the fasting blood glucose level of the high‐fat diet mice decreased by 24.93% after 5 weeks of MBPs dietary intervention (245 mg/kg/day) (Li et al., 2022), which was significantly better than that of black soy protein peptide (about 3.9%, 450 mg of supplement/day for 12 weeks) (Kwak et al., 2010), but was lower than that of soybeans (about 34%, 47.5 mg/kg/day, 3 weeks) (Jiang, Yan, et al., 2018) and black bean (53%, 150 mg/kg BW/day, 10 days) (Mojica et al., 2017).…”